Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07392892 · ClinicalTrials.gov registry record · Phase 2
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
A Phase 2 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 840
- Enrollment target
NCT07392892 is a Phase 2 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 840 participants.
The verdict
NCT07392892, a Phase 2 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 840 participants
- Enrollment target
Study Summary
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it. * In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better. The treatment will be given in repeated time periods called cycles.
Interventions
- BIOLOGICAL PF-08634404
- BIOLOGICAL Nivolumab
- DRUG Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2026-05-14 |
| Est. Completion | 2032-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07392892
The ClinicalTrials.gov registry entry for NCT07392892 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-08634404 is the first listed.
NCT07392892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07392892 about?
NCT07392892 is a clinical study titled "Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer". This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must...
What is the current status of trial NCT07392892?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 840 participants. The study started on 2026-05-14. Estimated completion is 2032-07-21.
What interventions are being tested in trial NCT07392892?
The interventions under investigation include: PF-08634404 (BIOLOGICAL), Nivolumab (BIOLOGICAL), Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07392892?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.